Edition:
United Kingdom

Seattle Genetics Inc (SGEN.OQ)

SGEN.OQ on NASDAQ Stock Exchange Global Select Market

55.26USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$55.26
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
348,771
52-wk High
$71.31
52-wk Low
$45.31

Select another date:

Thu, Nov 9 2017

BRIEF-SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS (BRENTUXIMAB VEDOTIN)

* SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA (PCALCL) AND CD30-EXPRESSING MYCOSIS FUNGOIDES (MF)

BRIEF-Seattle Genetics, Astellas initiate phase 1b trial for Enfortumab Vedotin

* Seattle Genetics and Astellas initiate phase 1B trial of Enfortumab Vedotin in combination with immune checkpoint inhibitor therapies in locally advanced or metastatic urothelial cancer

BRIEF-Seattle Genetics submits supplemental license application for Adcetris

* Seattle genetics submits supplemental biologics license application to FDA for Adcetris (brentuximab vedotin) in frontline advanced hodgkin lymphoma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Seattle Genetics reports Q3 earnings $0.34/shr

* Seattle Genetics reports third quarter 2017 financial results

BRIEF-Seattle Genetics ‍announces additional clinical collaborations to evaluate SGN-LIV1A in triple negative breast cancer​

* Says ‍announces additional clinical collaborations to evaluate SGN-LIV1A in triple negative breast cancer​

BRIEF-Astellas and Seattle Genetics initiate trial of enfortumab vedotin for ureter cancer patients

* Astellas and Seattle Genetics initiate pivotal trial of Enfortumab Vedotin for patients with locally advanced or metastatic urothelial cancer

BRIEF-Seattle Genetics and Astellas initiate pivotal trial of enfortumab vedotin

* Seattle Genetics and Astellas initiate pivotal trial of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer

BRIEF-Genmab and Seattle Genetics to start Phase II study of tisotumab vedotin

* Genmab and Seattle Genetics to initiate new study of novel antibody-drug conjugate tisotumab vedotin in cervical cancer

BRIEF-Genmab and Seattle Genetics to start study of Tisotumab Vedotin in cervical cancer

* GENMAB AND SEATTLE GENETICS TO INITIATE NEW STUDY OF NOVEL ANTIBODY-DRUG CONJUGATE TISOTUMAB VEDOTIN IN CERVICAL CANCER

CORRECTED-BRIEF-Seattle Genetics receives FDA breakthrough therapy designation for lymphoma drug

* Seattle Genetics receives FDA breakthrough therapy designation for adcetris® (brentuximab vedotin) in frontline advanced hodgkin lymphoma

Select another date: